ClinicalTrials.gg
CompletedNCT07126249Updated Aug 17, 2025

A Study to Evaluate the the Bioequivalence of Two Different Pimicotinib Capsules in Healthy Subjects

A Phase 1 interventional study of pimicotinib capsules in Pharmacokinetics, sponsored by Abbisko Therapeutics Co, Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-17.

Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a study to evaluate bioequivalence and tolerability of two different pimicotinib capsules in healthy subjects under fasting condition. 38 healthy subjects are planned to be enrolled and will be evenly randomized to either Study Sequence A or Study Sequence B . Subjects in Sequence A/Sequence B will receive a single 50 mg oral dose of test/reference pimicotinib in period 1 and cross over in period 2. Blood samples will be collected for PK analysis in totally 32 time-points.

02

Conditions studied

  • Pharmacokinetics
03

In context

Lead sponsor

Abbisko Therapeutics Co, Ltd is the lead sponsor of 38 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy subjects aged 18 to 50 years (inclusive) at screening;
  2. Weight ≥ 50.0 kg (male) or ≥ 45.0 kg (female);
  3. Normal or abnormal but not results in medical history, physical examination, clinical laboratory tests and other relevant examinations as assessed by the investigator at Screening;
  4. Male or female subjects of must agree to use effective methods of during the study and within 6 months after the last dose of product;
  5. Willing to participate in this study, understand the study procedures and sign the form prior to screening; willing to comply with the study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Past or current medical history of chronic or severe conditions in cardiovascular, respiratory, blood, liver, kidney, gastrointestinal, endocrine or nervous systems;
  2. Known or persistent mental disorders;
  3. Past history of gastric or intestinal surgery, or other operations;
  4. Dysphagia and inability to take the product orally;
  5. Intolerant to venipuncture, difficult to collect blood samples, and fear of needle sickness and blood;
  6. Known allergy to two or more kinds of foods and drugs; or allergic to pimicotinib or its ; and prone to allergic reactions such as rash and urticaria;
  7. History of infection within 30 days prior to screening;
  8. Symptoms of fatigue and pyrexia within 2 weeks prior to screening;
  9. Abnormal laboratory tests;
  10. Positive result for either of the following tests: serum Surface Antigen (HBsAg), Virus (HCV) antibody, (HIV) antibody, and treponema pallidum antibody;
  11. Participated in any clinical studies of drugs as a study subject and received the study drug within 3 months prior to screening;
  12. Previously participated in any other study related to pimicotinib and received pimicotinib;
  13. Used strong inhibitors or inducers of within 14 days prior to screening and at Screening or intending to use during the study;
  14. Have special diet requirements and cannot accept to take a unified dietary;
  15. Consumption of more than 14 units of alcohol per week within 3 months prior to signing the form, or a positive result for alcohol breath test on the day pre-dose, or unable to abstain from alcohol during the study;
  16. Consumption of more than 5 cigarettes per day within 3 months prior to signing the informed consent form, or unable to abstain from tobacco products during the study;
  17. Previous chronic consumption of excessive amount of tea, coffee, or caffeinated beverages or unable to abstain from caffeinated beverages during the study;
  18. Known history of drug abuse or positive for drug abuse screening test;
  19. Used over the counter or prescription drugs within 14 days prior to screening, or plan to use such drugs during the study;
  20. Donated or lost > 400 mL of blood within 3 months prior to screening; received blood transfusions or used blood products within 2 months prior to screening;
  21. Received vaccine within 2 months prior to screening, or plan to get vaccinated during the study;
  22. Significant abnormalities and judged by the investigator as clinical significance in vital signs;
  23. Heart rate- interval prolongation;
  24. Subjects involved in the design or conduct of this study and their immediate family members;
  25. Subjects who, in the opinion of the investigator, are not suitable for enrollment or may not be able to complete the study for other reasons.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Other
    pimicotinib (test capsule-reference capsule)

    subjects in sequence A will receive a single oral dose of 50 mg test capsule administered as 2 x 25 mg (the capsule is commercial formulation to be marketed) in period 1 day 1 and receive a single oral dose of 50 mg reference capsule administered as 2 x 25 mg (the capsule was used in phase 3 study Part 1) in period 2 day 1.

    Drug: pimicotinib capsules

  • Other
    pimicotinib (reference capsule-test capsule)

    subjects in sequence B will receive a single oral dose of 50 mg reference capsule administered as 2 x 25 mg (the capsule was used in phase 3 study Part 1) in period 1 day 1 and receive a single oral dose of 50 mg test capsule administered as 2 x 25 mg (the capsule is commercial formulation to be marketed) in period 2 day 1 .

    Drug: pimicotinib capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Peak concentration, the maximum observed plasma concentration of pimicotinib

    Time frame: Period 1& Period 2: pre-dose, postdose 15 minutes, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours, 96 hours, 120 hours, 144 hours, 192 hours and 240 hours.

  2. AUClast

    Area under the plasma concentration-time curve of pimicotinib from time 0 to the time of last measurable (non-BQL) concentration (calculated using the Linear Up Log Down trapezoidal method)

    Time frame: Period 1& Period 2: pre-dose, postdose 15 minutes, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours, 96 hours, 120 hours, 144 hours, 192 hours and 240 hours.

Secondary outcomes

  1. AE

    To evaluate the safety following a single oral dose of the two different pimicotinib capsules under fasting conditions in healthy subjects,The relationship of each adverse event to the investigational product will be assessed by CTCAE v5.0.

    Time frame: through study completion, an average of 26 days

  2. AUC0-∞

    Area under the plasma concentration-time curve of pimicotinib from time 0 to infinity, calculated as: AUC0-∞=AUClast +Clast/λz; Clast refers to the last measurable (non-BQL) plasma concentration of pimicotinib

    Time frame: Period 1& Period 2: pre-dose, postdose 15 minutes, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours, 96 hours, 120 hours, 144 hours, 192 hours and 240 hours.

  3. t1/2

    Elimination half-life

    Time frame: Period 1& Period 2: pre-dose, postdose 15 minutes, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours, 96 hours, 120 hours, 144 hours, 192 hours and 240 hours.

  4. CL/F

    Total apparent clearance after a single oral dose

    Time frame: Period 1& Period 2: pre-dose, postdose 15 minutes, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours, 96 hours, 120 hours, 144 hours, 192 hours and 240 hours

  5. Vz/F

    Apparent volume of distribution after a single oral dose

    Time frame: Period 1& Period 2: pre-dose, postdose 15 minutes, 0.5 hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 24 hours, 48 hours, 96 hours, 120 hours, 144 hours, 192 hours and 240 hours

07

Study locations

1 site
  • The First Hospital of Jilin University
    Changchun, Jilin, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Jun 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2025
First posted
Aug 17, 2025
StartActual
May 13, 2025
Primary completionActual
Jun 6, 2025
CompletionActual
Jun 16, 2025
Last update
Aug 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07126249
Responsible party
Sponsor
First posted
Aug 17, 2025
Start date
May 13, 2025
Primary completion
Jun 6, 2025
Completion
Jun 16, 2025
Last update
Aug 17, 2025

Study contacts

Yanhua Ding, Doctor
principal investigator · The First Hospital of Jilin University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pimicotinib

Start the discussion